Drug Trial Radar · NCT00361504
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
Last checked: Nov 19, 2026Latest source record: Apr 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,123
Actual
Start
Nov 2006
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Grünenthal GmbH
- First posted
- Aug 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis.
Conditions
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Lower Back Pain
- Pain
Interventions
Oxycodone CRDrug
Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
Tapentadol (CG5503) ERDrug
Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: 52 weeks
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Mesa, Arizona
Site not named
Tucson, Arizona
Site not named
Anaheim, California
Site not named
Cudahy, California
Site not named
Encinitas, California
Site not named
San Diego, California
Site not named
Westlake Village, California
Site not named
Trumbull, Connecticut
Site not named
Chiefland, Florida
Site not named
Clearwater, Florida
Site not named
Jacksonville, Florida
Site not named
Oldsmar, Florida
Site not named
Atlanta, Georgia
Site not named
Cumming, Georgia
Site not named
Decatur, Georgia
Site not named
Perry, Georgia
Site not named
Suwanee, Georgia
Site not named
Woodstock, Georgia
Site not named
Indianapolis, Indiana
Site not named
Prairie Village, Kansas
Site not named
Topeka, Kansas
Site not named
Paducah, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Rockville, Maryland
Site not named
Wellesley Hills, Massachusetts
Site not named
Kalamazoo, Michigan
Site not named
Las Vegas, Nevada
Site not named
Mamaroneck, New York
Site not named
Williamsville, New York
Site not named
Raleigh, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Kettering, Ohio
Site not named
Medford, Oregon
Site not named
Duncansville, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Roanoke, Virginia
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.